These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1977408)

  • 1. Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease.
    Maj J; Rogóz Z; Skuza G; Sowińska H; Superata J
    J Neural Transm Park Dis Dement Sect; 1990; 2(2):101-12. PubMed ID: 1977408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592.
    Acquas E; Carboni E; de Ree RH; Da Prada M; Di Chiara G
    J Neurochem; 1992 Jul; 59(1):326-30. PubMed ID: 1613509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease.
    Ceravolo R; Piccini P; Bailey DL; Jorga KM; Bryson H; Brooks DJ
    Synapse; 2002 Mar; 43(3):201-7. PubMed ID: 11793426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurochemical and psychomotor interactions of new selective COMT inhibitors with clorgyline and nomifensine in levodopa-treated rats and mice.
    Törnwall M; Tuomainen P; Männistö PT
    Arch Int Pharmacodyn Ther; 1992; 320():5-20. PubMed ID: 1300941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COMT inhibition in the treatment of Parkinson's disease.
    Ruottinen HM; Rinne UK
    J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues.
    Zürcher G; Colzi A; Da Prada M
    J Neural Transm Suppl; 1990; 32():375-80. PubMed ID: 2089102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats.
    Brannan T; Martínez-Tica J; Yahr MD
    Neurology; 1992 Mar; 42(3 Pt 1):683-5. PubMed ID: 1549240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study.
    Kaakkola S; Wurtman RJ
    Brain Res; 1992 Aug; 587(2):241-9. PubMed ID: 1381981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP(+)-lesioned mice.
    Himori N; Mishima K
    Experientia; 1994 Oct; 50(10):939-42. PubMed ID: 7957769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
    Männistö PT; Tuomainen P; Tuominen RK
    Br J Pharmacol; 1992 Mar; 105(3):569-74. PubMed ID: 1628144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
    Napolitano A; Zürcher G; Da Prada M
    Eur J Pharmacol; 1995 Feb; 273(3):215-21. PubMed ID: 7737328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
    Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K;
    Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Microdialysis study of tolcapone effect during blockage of neuronal dopamine reuptake caused by GBR-12909].
    Budygin EA; Gaĭnetdinov RR; Raevskiĭ KS; Li IH; Mannisto PT
    Eksp Klin Farmakol; 1997; 60(5):8-10. PubMed ID: 9483396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sexually dimorphic effects of catechol-O-methyltransferase (COMT) inhibition on dopamine metabolism in multiple brain regions.
    Laatikainen LM; Sharp T; Harrison PJ; Tunbridge EM
    PLoS One; 2013; 8(4):e61839. PubMed ID: 23613951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
    Limousin P; Pollak P; Pfefen JP; Tournier-Gervason CL; Dubuis R; Perret JE
    Clin Neuropharmacol; 1995 Jun; 18(3):258-65. PubMed ID: 8635184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.
    Napolitano A; Del Dotto P; Petrozzi L; Dell'Agnello G; Bellini G; Gambaccini G; Bonuccelli U
    Clin Neuropharmacol; 1999; 22(1):24-9. PubMed ID: 10047930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum.
    Kaakkola S; Wurtman RJ
    J Neurochem; 1993 Jan; 60(1):137-44. PubMed ID: 8417137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats.
    Huotari M; Passlin M; Nordberg HL; Forsberg M; Kotisaari S; Tuomisto L; Shintani F; Tanaka KF; Reenilä I; Laitinen K; Männistö PT
    J Neurosci Methods; 2001 Aug; 109(1):47-52. PubMed ID: 11489299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catechol O-methyltransferase: characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitors.
    Männistö PT
    Adv Pharmacol; 1998; 42():324-8. PubMed ID: 9327906
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence of COMT inhibition on levodopa pharmacology and therapy.
    Goetz CG
    Neurology; 1998 May; 50(5 Suppl 5):S26-30. PubMed ID: 9591519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.